$8.36
3.35% today
NYSE, Apr 03, 06:50 pm CET
ISIN
US90240B1061
Symbol
TYRA
Sector
Industry

Tyra Bioscience Stock price

$8.65
-2.56 22.84% 1M
-13.73 61.35% 6M
-5.25 37.77% YTD
-8.13 48.45% 1Y
-2.44 22.00% 3Y
-17.35 66.73% 5Y
-17.35 66.73% 10Y
NYSE, Closing price Wed, Apr 02 2025
-0.07 0.80%
ISIN
US90240B1061
Symbol
TYRA
Sector
Industry

Key metrics

Market capitalization $438.99m
Enterprise Value $103.77m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.28
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-104.20m
Free Cash Flow (TTM) Free Cash Flow $-70.44m
Cash position $341.44m
EPS (TTM) EPS $-1.51
P/E forward negative
Short interest 14.40%
Show more

Is Tyra Bioscience a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Tyra Bioscience Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Tyra Bioscience forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Tyra Bioscience forecast:

Buy
100%

Financial data from Tyra Bioscience

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.52 0.52
49% 49%
-
-0.52 -0.52
49% 49%
-
- Selling and Administrative Expenses 24 24
38% 38%
-
- Research and Development Expense 80 80
28% 28%
-
-104 -104
30% 30%
-
- Depreciation and Amortization 0.52 0.52
49% 49%
-
EBIT (Operating Income) EBIT -104 -104
30% 30%
-
Net Profit -86 -86
25% 25%
-

In millions USD.

Don't miss a Thing! We will send you all news about Tyra Bioscience directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tyra Bioscience Stock News

Neutral
PRNewsWire
7 days ago
- Three INDs cleared by US FDA for TYRA's proprietary precision small molecules - - TYRA-300 to be evaluated in three Phase 2 studies: SURF302 for Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC), BEACH301 for pediatric achondroplasia (ACH) and SURF301 for metastatic urothelial cancer (mUC) - - Cash, cash equivalents, and marketable securities of $341.4 million at YE 2024; runway...
Neutral
PRNewsWire
about 2 months ago
CARLSBAD, Calif. , Feb. 11, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences: Oppenheimer 35th Annual Healthc...
Neutral
PRNewsWire
2 months ago
CARLSBAD, Calif. , Jan. 22, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that two abstracts were accepted for presentation at the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI)...
More Tyra Bioscience News

Company Profile

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SNÅP, enables the rapid and precise refinement of structural design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.

Head office United States
CEO Todd Harris
Employees 60
Founded 2018
Website www.tyra.bio

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today